Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 5/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 5/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798454 | 1.00 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6780551 | 0.95 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7959740 | 0.93 | GRIA1 (0.87) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7103934 | 0.89 | GRIA1 (0.81) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8810839 | 0.88 | GRIA1 (0.87) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6784577 | 0.84 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6785878 | 0.79 | GRIA1 (0.88) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6783780 | 0.79 | GRIA1 (0.66) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6791392 | 0.79 | GRIA1 (0.64) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8684519 | 0.78 | GRIA1 (0.64) | GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011076946-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER | Universidad Del País Vasco (ES) | 2011-06-30 | — | — | WO | claimed |
| US-20080113969-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | CREDIT SUISSE AG | 2008-05-15 | — | — | US | claimed |
| US-20080108603-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-08 | — | — | US | claimed |
| US-20080108622-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | CREDIT SUISSE AG | 2008-05-08 | — | — | US | claimed |
| US-7192931-B2 | Treatment of demyelinating diseases | NEUREN PHARMACEUTICALS LTD. (NZ) | 2007-03-20 | — | — | US | claimed |
| WO-2004069195-A2 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS OF THE AIRWAYS | IVAX CORPORATION (US) | 2004-08-19 | — | — | WO | claimed |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | claimed |
| US-20040053850-A1 | Treatment of demyelinating diseases | ENDOCRINZ LIMITED (NZ) | 2004-03-18 | — | — | US | claimed |
| US-6703391-B2 | THROMBOSIS, BRAIN DISORDERS, CARDIOVASCULAR DISORDERS, ALZHEIMER'S DISEASE, HUNTINGTON DISEASES | NEUROSEARCH A/S (DK) | 2004-03-09 | — | — | US | claimed |
| EP-1359933-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | Neuronz Limited (NZ) | 2003-11-12 | — | — | EP | claimed |
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-06-19 | — | — | US | claimed |
| WO-2002030447-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | NEURONZ LTD. (NZ) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030448-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | NEURONZ LTD. (NZ) | 2002-04-18 | — | — | WO | claimed |
| EP-0664807-B1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER LAMBERT CO (US) | 1997-09-10 | — | — | EP | claimed |
| EP-0664807-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS. | WARNER LAMBERT CO (US) | 1995-08-02 | — | — | EP | claimed |
| WO-1994009000-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| EP-0664807-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS. | WARNER LAMBERT CO (US) | 1995-08-02 | — | — | EP | disclosed |
| WO-1994009000-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | CHRNA3, CHRNA7, CHRNB3 | GRIA1 41/4885GRIA2 25/4885GRIA3 16/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GRIA1 346/4885GRIA2 127/4885GRIA3 170/4885 |
| US-20080113969-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | ADORA1, ADORA3, OPRL1 | GRIA1 73/4885GRIA2 109/4885GRIA3 69/4885 |
| US-20080108603-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | ADORA1, ADORA3, OPRL1 | GRIA1 73/4885GRIA2 109/4885GRIA3 69/4885 |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | LTB4R2, LTB4R, LTC4S | GRIA1 2085/4885GRIA2 2341/4885GRIA3 2201/4885 |
| US-20080108622-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | ADORA1, ADORA3, OPRL1 | GRIA1 73/4885GRIA2 109/4885GRIA3 69/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | GRIA1 346/4885GRIA2 127/4885GRIA3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.